FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

FDA Drug Safety Podcasts

Innhold levert av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

5+ y ago 3:00

MP3•Episoder hjem

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

62 episoder

#Science #Fitness #Biology #Medicine #Government #Center For Drug Evaluation #Drug Administration #U.S. Food

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

FDA Drug Safety Podcasts

0-10 subscribers

published 5+ y ago

Del

MP3•Episoder hjem

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

62 episoder

#Science #Fitness #Biology #Medicine #Government #Center For Drug Evaluation #Drug Administration #U.S. Food

Alle episoder

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema

Lik FDA Drug Safety Podcasts

Podcaster verdt å lytte til

FDA Drug Safety Podcasts « » FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

Podcaster verdt å lytte til

Velkommen til Player FM!

Lik FDA Drug Safety Podcasts

Hurtigreferanseguide

FDA Drug Safety Podcasts « »
FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering